Precigen in the NEWS Precigen (PGEN) announced that the United States (FDA) has approved the product  PAPZIMEOS™ (zopapogene imadenovec-drba) for the treatment of adults with recurrent respiratory papillomatosis (RRP). PAPZIMEOS is the first and only FDA-approved therapy for the treatment of adults with RRP. Precigen completed submission of the rolling Biologics License Application (BLA) in December 2024 . . . This content is for paid subscribers. Please click here …